BOSTON – Cycle Pharmaceuticals Limited (Cycle) has announced the expansion of its patient support program, Cycle Vita™, to include BAFIERTAM® (monomethyl fumarate) delayed-release capsules. This enhancement follows Cycle’s acquisition of Banner Life Sciences, LLC, further strengthening its commitment to Multiple Sclerosis (MS) care.
Starting April 1, 2025, new patients beginning BAFIERTAM therapy will have access to Cycle Vita’s comprehensive support services, including financial assistance, product education, process guidance, and clinical support. Patients already on BAFIERTAM before this date will continue receiving assistance through Banner Patient Support and will be seamlessly transitioned to Cycle Vita in collaboration with their healthcare providers. Cycle has emphasized its commitment to ensuring a smooth transition with no interruptions in treatment.
BAFIERTAM is an FDA-approved oral disease-modifying therapy for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It distinguishes itself from other fumarate-class therapies by requiring no dietary restrictions and no metabolic conversion.
With the inclusion of BAFIERTAM, Cycle now offers support for two oral MS medications, alongside TASCENSO ODT® (fingolimod). The expansion allows Cycle Vita’s specialized MS support team to assist more patients, reinforcing the company’s dedication to enhancing access to critical treatments and personalized patient care.
